Efficacy and safety of herbal medicine (Binafuxi granules) for the common cold with fever: A multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial.

"Declaration of competing interest The property right of Binafuxi granules belongs to the organizing institution (Xinjiang Yinduolan Pharmaceutical Co., Ltd.), which applied for an invention patent (Compound of Chinese traditional medicine for treating common cold with heat syndrome, and its preparation method and application. No. CN201910775844.6) in 2019. As an organizing institution, Xinjiang Yinduolan Pharmaceutical Co., Ltd., provided financial support for the project research. West China Hospital of Sichuan University is the leading investigating hospital for the Binafuxi granules phase II clinical trial, researchers from which designed the study and were responsible for the data analyses and the decision for manuscript submission. The organizing institution, as well as the authors from the organizing institution, who are J Li, L Huang and J Chen, had no role in the design of this study and does not have any responsibility for analyses, interpretation of the data, or the decision to submit results. The authors declare that they have no competing interests."

"Funding This study was financially supported by Xinjiang Yinduolan Pharmaceutical Co., Ltd., Xinjiang, China, and the authors, except J Li, L Huang and J Chen, were financially supported by Science & Technology Department of Sichuan Province (2021YFS0271)."

"Trial Registration This trial was registered at Chinese Clinical Trial Registry (ChiCTR-IIR-17013379)."